- Report
- October 2023
- 68 Pages
Global
From €6721EUR$6,995USD£5,770GBP
- Report
- August 2022
- 119 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,186GBP
Pyridostigmine is a medication used to treat myasthenia gravis, a rare autoimmune disorder that causes muscle weakness. It works by increasing the amount of acetylcholine, a neurotransmitter, in the body. Pyridostigmine is available in both oral and injectable forms. It is usually taken in combination with other medications to treat myasthenia gravis. Common side effects include nausea, vomiting, and abdominal pain.
The Pyridostigmine market is a niche market, as myasthenia gravis is a rare disorder. It is mainly composed of generic manufacturers, as the patent for the drug has expired. The market is highly competitive, with many companies offering similar products.
Companies in the Pyridostigmine market include Mylan, Teva Pharmaceuticals, Sandoz, and Sun Pharmaceuticals. Show Less Read more